Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris

Next Previous
Search
Trial Profile

A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sarecycline (Primary)
  • Indications Acne vulgaris
  • Focus Registrational; Therapeutic Use
  • Sponsors Almirall S.A.; Warner Chilcott

    • Most Recent Events

    • 21 Mar 2023 Results post hoc analysis of pooled data from NCT02320149, NCT02322866, assessing Efficacy of Sarecycline for Facial Acne Vulgaris in Patients With Skin of Color, presented at the American Academy of Dermatology annual Meeting 2023
    • 21 Mar 2023 Results of post hoc analysis of pooled data from NCT02320149, NCT02322866; evaluating the efficacy of sarecycline for truncal (chest and back) acne in patients with skin of color, presented at the American Academy of Dermatology annual Meeting 2023
    • 21 Mar 2023 Results of post hoc analysis from NCT02320149, NCT02322866, presented at the American Academy of Dermatology annual Meeting 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top